Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China

Overview of attention for article published in Frontiers in Pharmacology, November 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 9,023 followers.

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment ... https://t.co/7uo9S0opDw

RT @ALCASEItalia: Un nuovo immunoterapico, il CAMRELIZUMAB, made in China... https://t.co/yYu5jFoOwJ

Un nuovo immunoterapico, il CAMRELIZUMAB, made in China... https://t.co/yYu5jFoOwJ

New article: Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China https://t.co/FmnJsDMrIA #lungcancer #oncology https://t.co/6qYnv91y0R

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.